文献速递神经免疫

拟议生物类似药那他珠单抗(PB006)治疗复发缓解型多发性硬化患者的疗效与安全性:Antelope 3期随机临床试验

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

Antelope 3期随机试验在7国48中心比较生物类似药那他珠单抗(biosim-NTZ)PB006与参照那他珠单抗(ref-NTZ)治疗复发缓解型多发性硬化。264例患者随机接受biosim-NTZ 131例或ref-NTZ 133例,24周新活动病灶累积数最小二乘均值biosim-NTZ 0.34 vs ref-NTZ 0.45,模型均值差0.17(95%CI -0.61至0.94,在预设界值±2.1内)。两组次要疗效、安全性、耐受性及免疫原性均无显著差异。

要点

  • 24周新活动病灶累积数biosim-NTZ组0.34 vs ref-NTZ组0.45,均值差0.17(95%CI -0.61至0.94),在预设界值±2.1内。
  • 两组次要疗效终点、安全性、耐受性及免疫原性评估均无显著差异。
  • 3期试验支持PB006作为ref-NTZ治疗复发缓解型多发性硬化的生物类似药替代选择。

核心结论

  • 在测试条件下,biosim-NTZ与ref-NTZ在复发缓解型多发性硬化患者的疗效、安全性和免疫原性方面相匹配。
  • 该3期试验支持将拟议的biosim-NTZ作为ref-NTZ治疗复发缓解型多发性硬化的生物类似药替代选择。

研究设计与样本

  • Antelope试验为3期、平行组、随机、阳性对照研究,于2019年10月至2021年3月进行,末例患者随访访视于2021年8月23日。
  • 研究在7个国家的48个中心开展;筛查531例18至60岁复发缓解型多发性硬化患者,266例在随机化前按研究标准被排除。
  • 合格参与者需前一年内至少1次记录在案的复发,且至少1个钆增强T1加权病灶或至少9个T2加权脑病灶,Kurtzke扩展残疾状态量表评分0至5.0(含),筛查时John Cunningham病毒指数≤1.5;1例患者在给药前撤回知情同意。
  • 干预为每4周静脉输注biosim-NTZ 300 mg或ref-NTZ 300 mg(1:1随机化),从第0周至第44周(研究结束访视:第48周);第24周时ref-NTZ组再次随机化,30例患者转换为biosim-NTZ至研究结束。

主要发现

  • 共264例参与者(平均[SD]年龄36.7[9.38]岁;162例[61.4%]女性)接受biosim-NTZ(n=131)或ref-NTZ(n=133)治疗。
  • 第24周时,biosim-NTZ与ref-NTZ治疗组之间新活动病灶累积数的模型均值差为0.17(最小二乘均值[SE]:biosim-NTZ 0.34[0.34];ref-NTZ 0.45[0.28];95%CI -0.61至0.94,在预设界值±2.1内)。
  • 两组在次要疗效终点、安全性、耐受性或免疫原性评估方面均未观察到显著差异。

关键数值与推荐

  • 主要终点为24周内磁共振成像新活动病灶累积数(新钆增强T1加权病灶及新发/扩大的T2加权病灶,不重复计数)。
  • 其他终点包括进一步磁共振成像参数、年化复发率及Kurtzke扩展残疾状态量表评分。
  • 安全性、耐受性和免疫原性评估包括不良事件、实验室评估及抗John Cunningham病毒抗体和抗那他珠单抗抗体阳性。
  • 试验注册:ClinicalTrials.gov标识符NCT04115488。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment. OBJECTIVE: To evaluate matching efficacy, safety, and immunogenicity between biosim-NTZ and reference natalizumab (ref-NTZ) in patients with relapsing-remitting MS (RRMS). DESIGN, SETTING, AND PARTICIPANTS: The Antelope trial was a phase 3, parallel-group, randomized, active-controlled study, conducted between October 2019 and March 2021, with last patient follow-up visit on August 23, 2021. The study took place in 48 centers in 7 countries. Of 531 patients with RRMS aged 18 to 60 years screened, 266 were excluded before randomization in line with study criteria. Eligible participants had 1 or more documented relapse within the previous year and either 1 or more gadolinium-enhancing T1-weighted or 9 or more T2-weighted brain lesions, Kurtzke Expanded Disability Status Scale score of 0 to 5.0 (inclusive), and John Cunningham virus index of 1.5 or less at screening. One patient withdrew consent before dosing. INTERVENTIONS: Intravenous infusions every 4 weeks of biosim-NTZ, 300 mg, or ref-NTZ, 300 mg (1:1 randomization), from week 0 to week 44 (end-of-study visit: week 48). At week 24, the ref-NTZ group was rerandomized and 30 patients were switched to biosim-NTZ for the remainder of the study. MAIN OUTCOMES AND MEASURES: The primary end point was the cumulative number of new active lesions on magnetic resonance imaging (new gadolinium-enhancing T1-weighted lesions and new/enlarging T2-weighted lesions without double counting) over 24 weeks. Additional end points included further magnetic resonance imaging parameters, annualized relapse rate, and Kurtzke Expanded Disability Status Scale score. Safety, tolerability, and immunogenicity assessments included adverse events, laboratory evaluations, and positivity for anti-John Cunningham virus antibodies and antinatalizumab antibodies. RESULTS: A total of 264 participants (mean [SD] age, 36.7 [9.38] years; 162 [61.4%] female) received treatment with biosim-NTZ (n = 131) or ref-NTZ (n = 133). At week 24, the model-based mean difference in cumulative number of new active lesions between biosim-NTZ and ref-NTZ treatment groups was 0.17 (least square means [SE]: biosim-NTZ, 0.34 [0.34]; ref-NTZ, 0.45 [0.28]; 95% CI, -0.61 to 0.94 within the prespecified margins of ±2.1). No significant differences between treatment groups were observed across secondary efficacy end points, safety, tolerability, or immunogenicity assessments. CONCLUSIONS AND RELEVANCE: Biosim-NTZ matched ref-NTZ in efficacy, safety, and immunogenicity for patients with RRMS in the tested setting. This phase 3 trial supports proposed biosim-NTZ as a biosimilar alternative to ref-NTZ for treating RRMS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04115488.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hemmer B, Wiendl H, Roth K, et al. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 36689214. doi:10.1001/jamaneurol.2022.5007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。